Clinical Trials Directory

Trials / Completed

CompletedNCT01614691

Safety and Efficacy of SPARC1203 in Allergic Rhinitis

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
159 (actual)
Sponsor
Sun Pharma Advanced Research Company Limited · Industry
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

This study will assess safety and efficacy of SPARC1203 delivered via nasal spray in patients with allergic rhinitis

Conditions

Interventions

TypeNameDescription
DRUGSPARC1203Active
DRUGPlaceboPlacebo

Timeline

Start date
2012-06-01
Primary completion
2012-11-01
Completion
2013-03-01
First posted
2012-06-08
Last updated
2019-05-03

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT01614691. Inclusion in this directory is not an endorsement.